KIP

KIP (Korea Investment Partners) is Asia's leading venture capital institution. Since its establishment in Seoul, South Korea in 1986, it has maintained a steady pace of investment and gradually grown into a venture capital institution based in Asia with investment tentacles reaching many regions around the world. KIP's investment portfolio companies are located in Asia, Europe, America and other places, with more than 1,000 global investment cases, of which more than 300 have been listed on the secondary markets of various countries/regions, with a cumulative asset management scale of more than 5 billion US dollars. KIP entered China in 2008 and set up offices in Shanghai, Beijing, Guangzhou, Shenzhen, and Chengdu, and established multiple RMB funds with a total scale of more than 3 billion. It has invested in dozens of industry-leading companies in high-tech, corporate services, bio-health, and mass consumption. Representative cases include Henlius (02696.HK), Weimob (02013.HK), Didi Chuxing (DIDI.US), Boqi Pet (BQ.US), and Wankayi Lian (01762.HK), Ascentage Pharmaceuticals (06855.HK), Peijia Medical (09996.HK), Kain Technology (688607.SH), Energy Chain Group (NASDAQ: NAAS), New West Mystery, Quanyuantang, Doraemon, Gaoxian Robot, Keralala, etc.

Website: www.kipvc.cn